Practical treatment of Helicobacter pylori
Authors:
- Sinéad M. SmithSSSinéad M. Smith
- Rana B. HaiderRHRana B. Haider
- Humphrey O’connorHOHumphrey O’connor
- Deirdre McNamaraDMDeirdre McNamara
- Colm O’morainCOColm O’morain
- 1 August 2014
- journal article
- review article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 26 (8) , 819-825
Abstract
Eradication rates of first-line triple therapy for Helicobacter pylori infection have fallen in the recent years. The main reasons for treatment failure are poor compliance due to complicated treatment regimens and the emergence of antibiotic-resistant strains of H. pylori. Treatment failure is a cause for concern with regard to the complications of H. pylori infection, which include gastric and peptic ulcers, gastric cancer and mucosa-associated lymphoid tissue lymphoma. This review describes considerations for optimizing standard first-line triple therapy, as well as alternatives to the standard first-line treatment, such as bismuth quadruple therapy, sequential therapy, concomitant therapy and hybrid therapy. Studies using levofloxacin-based and rifabutin-based regimens for the treatment of multiresistant infections have also been reviewed. The current most up-to-date systematic reviews and meta-analyses comparing the efficacy of these treatments have been discussed, in light of the recent antimicrobial susceptibility testing data, regional antibiotic resistance rates and the Maastricht IV guidelines on the management of H. pylori infection.Keywords
This publication has 40 references indexed in Scilit:
- Meta-Analysis of Bismuth Quadruple Therapy versus Clarithromycin Triple Therapy for Empiric Primary Treatment of Helicobacter pylori InfectionDigestion, 2013
- Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical TrialsPLOS ONE, 2013
- Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pyloriClinical and Experimental Gastroenterology, 2012
- Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysisWiener klinische Wochenschrift, 2010
- Helicobacter pylori treatment in the era of increasing antibiotic resistanceGut, 2010
- Helicobacter pylori: gastric cancer and beyondNature Reviews Cancer, 2010
- Helicobacter pyloriInfectionNew England Journal of Medicine, 2010
- American College of Gastroenterology Guideline on the Management of Helicobacter pylori InfectionAmerican Journal of Gastroenterology, 2007
- The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysisGut, 2007
- Quinolone Resistance in Helicobacter pylori Isolates in GermanyAntimicrobial Agents and Chemotherapy, 2007